Increasing Trend in the Number of Severe Hypoglycemia Patients in Korea

Jin Taek Kim¹, Tae Jung Oh², Ye An Lee², Jun Ho Bae¹, Hyo Jeong Kim¹, Hye Seung Jung³, Young Min Cho², Kyong Soo Park², Soo Lim³, Hak Chul Jang³, Hong Kyu Lee¹

¹Department of Internal Medicine, Eulji University Hospital, Eulji University College of Medicine, Seoul,
²Department of Internal Medicine, Seoul National University College of Medicine, Seoul,
³Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Background: To investigate whether the number of subjects with severe hypoglycemia who are brought to a hospital emergency department is increasing and to identify whether there have been changes in the demographic and clinical characteristics of those subjects.

Methods: We analyzed data from the Emergency Departments of two general hospitals in Seoul, Korea. We included data from all adult subjects with type 2 diabetes who presented to an emergency department with severe hypoglycemia between January 1, 2004 and December 30, 2009.

Results: A total of 740 cases of severe hypoglycemia were identified. The mean subject age was 69±12 years, mean duration of diabetes was 13.8±9.3 years, and 53.2% of subjects were receiving insulin therapy. We observed a sharp rise in the number of cases between 2006 and 2007. Stages 3-5 chronic kidney disease was diagnosed in 31.5% of subjects, and low C-peptide levels (<0.6 ng/mL) were found in 25.5%. The mean subject age, duration of diabetes, HbA1c level, and renal and insulin secretory function values did not change significantly during the study period. The proportion of glimepiride use increased, while use of gliclazide decreased among sulfonylurea users. Use of insulin analogues increased, while use of NPH/RI decreased among insulin users.

Conclusion: We identified a sharp increase in the number of subjects with severe hypoglycemia presenting to an emergency room since 2006. The clinical characteristics of these subjects did not change markedly during the study period. Nationwide studies are warranted to further clarify this epidemic of severe hypoglycemia.

Keywords: Emergency Department; Epidemiology; Severe hypoglycemia

INTRODUCTION

The epidemic of diabetes mellitus is a worldwide problem, and Korea is no exception. While proper glucose control is a mainstay for the prevention and management of diabetes-related complications, hypoglycemia remains a major problem associated with this disease [1-3]. Mild cases of hypoglycemia can be managed by the subject; however, severe hypoglycemia is accompanied by change in consciousness and can lead to trauma, injury, and even death in rare cases [4].
does not reduce mortality due to cardiovascular disease (CVD) in subjects with type 2 diabetes mellitus and may actually increase CVD risk, especially in subjects with pre-existing coronary heart disease (CHD) [5-7]. These trials have also shown that achieving rather aggressive HbA1c levels (<6.5%) is associated with a three-fold increased risk of hypoglycemia.

We recently noted that there might be a hypoglycemia epidemic in our community, as we were seeing more hypoglycemic subjects admitted to hospitals via the emergency department. We hypothesized that recent emphasis on glycemic control and changes in anti-diabetic medications may be influencing the incidence of severe hypoglycemia.

The aims of this study were to investigate whether the number of subjects with severe hypoglycemia presenting to an emergency department has increased in recent years and to identify whether there were changes in the demographic and clinical characteristics of those subjects. We also aimed to investigate if there have been changes in sulfonylurea or insulin use in these subjects.

**METHODS**

**Research design and methods**

Clinical data from the Emergency Departments of two general hospitals (Seoul National University Hospital and Eulji University Hospital) in Seoul were first obtained from the hospital databases. We included all adult subjects (aged ≥18 years) with type 2 diabetes mellitus who presented to the Emergency Department with severe hypoglycemia between January 1, 2004 and December 30, 2009. We searched for the following International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9CM) codes to identify potential episodes of severe hypoglycemia: 1) hypoglycemic coma in diabetes mellitus (250.3); 2) hypoglycemic coma (251.0); 3) other specified hypoglycemia (251.1); 4) hypoglycemia, unspecified (251.2). We then had three medical doctors (J.T. Kim, T.J. Oh, Y.A. Lee) review the medical records of all subjects for validation of the events and to obtain data on related clinical factors. We only included subjects with severe hypoglycemia, defined as a serum glucose level less than 60 mg/dL and the need for intervention to recover from the hypoglycemic event [8].

Using the subjects’ medical records, we obtained data on sex, age, height, weight, duration of diabetes, anti-diabetic treatment, the inciting factor for hypoglycemia, alcohol consumption, co-morbidities, and co-medications. In subjects taking both insulin and anti-diabetic medications, only insulin use was analyzed; for subjects taking multiple anti-diabetic oral medications, only sulfonylurea use was analyzed. The presence of diabetic macro- and microvascular complications were investigated. Data on HbA1c and fasting plasma C-peptide levels, complete blood counts, serum chemistries, and random urine microalbumin/creatinine ratios were obtained. The most recent HbA1c data prior to the hypoglycemic episode was used for analysis. We used an abbreviated MDRD equation for estimating glomerular filtration rate (GFR) [9], as follows: estimated GFR (mL/min/1.73 m²) = 186 × (creatin/88.4) × (age)-0.203 × (0.742, if female) × (1.210, if black). Stages 3-5 chronic kidney disease (CKD) was defined when the eGFR was less than 60 mL/min/1.73 m² [10]. A low C-peptide level was defined as that less than 0.6 ng/dL [11]. The institutional review board for each hospital approved the study protocol.

**Statistical analysis**

All data are presented as mean±standard deviation. Group differences in means were tested by ANOVA or the Kruskall Wallis Test, as appropriate. Group differences in nominal variables were tested using the chi-square test. We analyzed trends over time using the chi-square test for linear trend and linear regression. Two-tailed P values <0.05 were considered statistically significant. Statistical analysis was conducted using commercially available software (SPSS version 15.0; SPSS Inc., Chicago, IL, USA).

**RESULTS**

A total of 740 cases of severe hypoglycemia were identified, and the clinical characteristics of the patients are presented in Table 1. The mean subject age was 69±12 years old; 49.6% percent of subjects were male; the mean duration of diabetes was 13.8±9.3 years; mean body mass index was 23.2±3.8; and 53.2% of subjects were receiving insulin therapy. We noted a rather sharp increase in hypoglycemia cases in 2007 in both hospitals, and the level remained high for the remainder of the study period (Table 2). The number of severe hypoglycemia cases in 2009 (n=185) was 2.8-fold higher than the number in 2004 (n=66) (Table 2). During the same period, the total number of subjects who visited the emergency rooms of these hospitals steadily increased by 1.4-fold (2004, n=54, 405; 2009, n=77, 373) (Table 2).

Subjects visiting the emergency room due to severe hypo-
glycemia were more commonly in their seventies (n = 287, 38.8%), sixties (n = 191, 25.8%), or eighties (n = 121, 16.4%), in order of descending frequency (Fig. 1). When we divided the subjects into five groups according to age (≤50, 51-60, 61-70, 71-80, and ≥81 years), there were no differences in duration of diabetes, HbA1c level, or serum creatinine level (Table 3). Insulin use and insulin secretory defects were more common in the younger age group, and stages 3-5 CKD was more common in the older age group (Table 3).

The number of severe hypoglycemia cases increased consistently in the two hospitals over the study period. Mean age, duration of diabetes, creatinine level, HbA1c level, insulin use, and C-peptide level did not change significantly during this period (Table 4). When we analyzed sulfonylurea and insulin use according to year of presentation, we found that the proportion of glimepiride use increased, while gliclazide use decreased among oral drug users; and insulin glargine/detemir use increased, while insulin NPH/RI use decreased among insulin users (Table 5).

**DISCUSSION**

Hypoglycemia is the principal problem associated with strict glycemic control. Our study indicates that the number of subjects with severe hypoglycemia requiring emergency department visits has increased in recent years. Several previous epidemiologic studies have suggested that the incidence of severe hypoglycemia has also increased [12], while one study indicated that the increasing number may be due to the increased prevalence of type 2 diabetes mellitus, and that the rate of hypo-

| Variable                  | No. | Value        |
|---------------------------|-----|--------------|
| Age, yr                   | 740 | 69 ± 12      |
| Sex, M/F, n (%)           | 740 | 367 (49.6)/374 (51.4) |
| Duration of diabetes      | 463 | 12 (6-19)    |
| BMI, kg/m²                | 144 | 23.2 ± 3.8   |
| Insulin user, n (%)       | 613 | 326 (53.2)   |
| HbA1c, %                  | 498 | 7.2 ± 1.6    |
| Creatinine, mg/dL         | 639 | 1.1 (0.8-1.6) |
| Stage 3-5 CKD (GFR<60 mL/min/1.73 m²), n (%) | 639 | 233 (31.5) |
| C-peptide, ng/mL          | 376 | 1.5 (0.5-3.1) |
| Decreased C-peptide (<0.6 ng/dL), n (%) | 376 | 96 (25.5) |

Data are presented as either mean ± standard deviation, median (IQR), or number (%). HbA1c level refers to the most recent test results prior to the severe hypoglycemia episode. BMI, body mass index; CKD, chronic kidney disease.

**Table 2. Number of severe hypoglycemia events and Emergency Department visits**

| Year | E |          |          |          |          |          |          |          |
|------|---|----------|----------|----------|----------|----------|----------|----------|
|      | N(H) | N(E) | % | N(H) | N(E) | % | N(H) | N(E) | % |
| 2004 | 14  | 30,711 | 0.46 | 52   | 23,694 | 2.19 | 66   | 54,405 | 1.21 |
| 2005 | 9   | 31,556 | 0.29 | 59   | 28,087 | 2.10 | 68   | 59,643 | 1.14 |
| 2006 | 19  | 32,927 | 0.58 | 45   | 30,164 | 1.49 | 64   | 63,091 | 1.01 |
| 2007 | 99  | 33,490 | 2.96 | 90   | 33,088 | 2.72 | 189  | 66,578 | 2.84 |
| 2008 | 85  | 36,860 | 2.31 | 83   | 34,645 | 2.40 | 168  | 71,505 | 2.35 |
| 2009 | 87  | 41,216 | 2.11 | 98   | 36,157 | 2.71 | 185  | 77,373 | 2.39 |

E, Eulji University Hospital; S, Seoul National University Hospital; N(H), number of severe hypoglycemia subjects; N(E), number of emergency department visits; %, proportion of severe hypoglycemia cases in Emergency Department visits.
Severe hypoglycemia in Korea

Glycemia in the diabetic population has not changed [13]. The prevalence of type 2 diabetes mellitus in Korea has steadily increased over the past 30 years; however, after the late 1990s, the maximum increase per year was estimated to be less than 10% [14-16]. Accordingly, it is inferable from our data that the incidence of severe hypoglycemia in the diabetic population has also increased in Korea.

This trend is particularly problematic since it is prevalent among older adult subjects: those aged 60 years or older comprised the majority (83.2%) of the study population. It is conceivable that severe hypoglycemia may occur more easily in older adult subjects with decreased cognitive function and ac-

Table 3. Comparison of clinical characteristics according to age

| Age group, yr | Duration of diabetes, yr | HbA1c, % | Creatinine, mg/dL | Stages 3-5 CKD, no. (%) | Insulin user, no. (%) | Low C-peptide, no. (%) |
|---------------|--------------------------|----------|-------------------|-------------------------|-----------------------|------------------------|
| <50           | 14 (7-16)                | 7.5±1.7  | 1.0 (0.7-1.8)     | 22 (55.0)               | 41 (89.1)             | 9 (37.5)               |
| N             | 31                       | 38       | 40                | 40                      | 46                    | 24                     |
| 51-60         | 11 (5-18)                | 7.6±1.8  | 1.0 (0.8-1.5)     | 39 (52.0)               | 54 (70.1)             | 18 (40.0)              |
| N             | 60                       | 52       | 75                | 75                      | 77                    | 45                     |
| 61-70         | 11 (7-17)                | 7.2±1.6  | 1.2 (0.9-1.9)     | 61 (38.1)               | 82 (52.9)             | 25 (27.8)              |
| N             | 113                      | 117      | 160               | 160                     | 155                   | 90                     |
| 71-80         | 11 (5-20)                | 7.1±1.5  | 1.1 (0.8-1.5)     | 81 (31.9)               | 107 (45.3)            | 32 (20.4)              |
| N             | 185                      | 195      | 254               | 254                     | 236                   | 157                    |
| ≥81           | 13 (8-22)                | 7.1±1.5  | 1.1 (0.8-1.4)     | 30 (27.3)               | 42 (42.4)             | 12 (20.0)              |
| N             | 74                       | 96       | 110               | 110                     | 99                    | 60                     |
| P value       | 0.611                    | 0.074    | 0.210             | <0.001                  | <0.001                | 0.038                  |

Data are presented as either mean±standard deviation, median (IQR), or number (%). N is the total number of subjects with available data in each age group. Significance at \( P < 0.05 \) according to ANOVA for duration of diabetes, HbA1c, and creatinine level. Significance at \( P < 0.05 \) according to chi-square test for stages 3-5 CKD, insulin user, and low C-peptide level.

CKD, chronic kidney disease.

Table 4. Comparison of clinical characteristics according to year of presentation with severe hypoglycemia

| Year | Age, yr | Duration of diabetes, yr | HbA1c, % | Creatinine, mg/dL | Insulin user, no. (%) | Low C-peptide, no. (%) |
|------|---------|--------------------------|----------|-------------------|-----------------------|------------------------|
| 2004 | 66.0±13.0 | 16 (7-20)                | 7.6±2.0  | 1.1 (0.9-1.7)     | 25 (67.6)             | 5 (19.2)               |
| N    | 66      | 27                       | 45       | 58                | 37                    | 26                     |
| 2005 | 70.6±10.0 | 14 (6-17)                | 6.9±1.3  | 1.2 (0.9-1.7)     | 24 (42.9)             | 6 (19.4)               |
| N    | 68      | 38                       | 49       | 52                | 56                    | 31                     |
| 2006 | 69.9±12.5 | 10 (3-15)                | 7.2±1.1  | 1.1 (0.8-1.5)     | 25 (45.5)             | 10 (37.0)              |
| N    | 64      | 38                       | 49       | 52                | 55                    | 27                     |
| 2007 | 68.6±13.0 | 14 (8-20)                | 7.3±1.7  | 1.1 (0.8-1.6)     | 92 (57.9)             | 20 (20.2)              |
| N    | 189     | 138                      | 129      | 167               | 159                   | 99                     |
| 2008 | 69.6±10.9 | 10 (7-18)                | 7.1±1.5  | 1.1 (0.8-1.5)     | 83 (57.6)             | 21 (21.9)              |
| N    | 168     | 111                      | 102      | 147               | 144                   | 96                     |
| 2009 | 69.3±11.9 | 12 (6-20)                | 7.3±1.6  | 1.1 (0.8-1.5)     | 77 (53.2)             | 34 (35.1)              |
| N    | 185     | 111                      | 124      | 163               | 162                   | 97                     |
| P value | 0.295 | 0.185 | 0.850 | 0.845 | 0.511 | 0.053 |

Data are presented in either mean±standard deviation, median (IQR), or number (%). N is the number of total subjects with available data in each year. Significant at \( P < 0.05 \) according to P for trend (linear by linear association) with regard to age, duration of diabetes, HbA1c, and creatinine level. Significance at \( P < 0.05 \) according to chi-square test for linear trend in insulin user and low C-peptide level.
Table 5. Comparison of sulfonylurea and insulin use according to year of presentation with severe hypoglycemia

| Year | Glimepiride | Gliclazide | Glibenclamide | NPH/RI | Premixed | Glargine/Detemir |
|------|-------------|------------|---------------|--------|----------|-----------------|
| 2004 | 1/4 (25.0)  | 1/4 (25.0) | 2/4 (50.0)    | 14/14 (100.0) | 0/14 (0)  | 0/14 (0)        |
| 2005 | 9/16 (56.3)| 4/16 (25.0)| 3/16 (18.8)   | 11/12 (91.7)  | 1/12 (8.3) | 0/12 (0)        |
| 2006 | 5/11 (45.5)| 4/11 (36.4)| 2/11 (18.2)   | 10/12 (83.3)  | 0/12 (0)  | 2/12 (16.7)     |
| 2007 | 21/31 (67.7)| 2/31 (6.5)| 8/31 (25.8)   | 32/53 (62.3)  | 9/53 (17.0)| 12/53 (20.8)    |
| 2008 | 14/24 (58.3)| 3/24 (12.5)| 7/24 (29.2)   | 25/47 (53.2)  | 8/47 (17.0)| 15/47 (29.8)    |
| 2009 | 22/27 (81.5)| 2/27 (7.4)| 3/27 (11.1)   | 22/47 (46.8)  | 15/47 (31.9)| 10/47 (21.3)    |

P value | **0.020** | **0.037** | **0.344** | **<0.001** | **0.001** | **0.013**

Data are presented as number/total number (%). Total number is the number of total subjects with available data in each year. Significance at $P<0.05$ according to chi-square test for linear trend.

In line with this finding, population-based studies in Scotland and Germany have demonstrated that severe hypoglycemia requiring emergency treatment is common among older adult subjects, and that age was a risk factor for severe hypoglycemia [17,18]. In contrast, a nationwide study in the United States showed that the rate of severe hypoglycemia is higher in younger (age <45 years) and very old (age ≥75 years) subjects [13]. A cohort study in the United States also showed that older subjects experience a lower incidence of hypoglycemia after investigating the frequency of severe hypoglycemia among subjects receiving insulin monotherapy [12]. One explanation for the controversy is that age serves as a marker for the subject’s type of diabetes, with the proportion of type 2 diabetes mellitus subjects increasing with age.

Renal insufficiency was common among these subjects: 31.5% of the study population had stages 3-5 CKD (GFR <60 mL/min/1.73 m²). A recent nationwide survey on diabetes complications in Korea showed that 30.3% of diabetics have microalbuminuria [19]. Insulin secretory defects were also common among these subjects; those with decreased C-peptide levels (<0.6 ng/mL) made up 25.5% of the total population. A study investigating C-peptide levels in a large number of Korean subjects with adult onset diabetes showed that 9.1% (922 of 10,172) had low C-peptide levels (<0.6 ng/mL) [20]. However, when we analyzed the clinical characteristics of our study subjects according to year of presentation, the increasing occurrence of severe hypoglycemia did not appear to be associated with known risk factors, such as glycemic control status, duration of diabetes, age, renal function, or insulin secretory function.

The proportion of insulin users decreased during the study period. Use of insulin glargine and premixed insulin increased, while use of insulin NPH and RI decreased. Among sulfonylurea users, the proportion of glimepiride users increased, while that of gliclazide users decreased. These changes in the use of sulfonylureas and insulin in hypoglycemia subjects may or may not be a reflection of changes in medication use due to the introduction of newer-generation drugs. Further investigation into changes in medication use in the type 2 diabetes mellitus population may reveal an association between change in anti-diabetic medication and incidence of hypoglycemia.

Another interesting finding of our study was the sharp increase in severe hypoglycemia after 2007. There is a need for a nationwide survey investigating if there have been changes in glycemic control status, anti-diabetic therapy, and diabetes education in type 2 diabetes mellitus subjects in recent years in order to draw any firm conclusion regarding the cause of this trend. Diabetes educators in Korea should recognize that the most common inciting cause of hypoglycemia reported by our study subjects was decreased or missed food intake. If HbA1c level goals are established, it is essential to educate the subjects about the potential risk of hypoglycemia and methods of avoiding and treating it.

There are several limitations to this study. The major limitation is that we collected data from only two hospitals located in the Korean capital city of Seoul. This limitation makes it difficult to extend the implications of our results throughout Korea and to other countries. Another limitation is the retrospective nature of our analysis. It is quite possible that data may have been missing from the subjects’ medical records, thus biasing the results. Since some cases of severe hypoglycemia are treated effectively at home or work by friends, relatives, or colleagues, the results of the current study may not reflect the entire sphere of severe hypoglycemia in our community.
In summary, we identified an increase in the number of severe hypoglycemia subjects presenting to emergency rooms since 2004. Severe hypoglycemia prevails among older adults, and renal insufficiency and decreased endogenous insulin secretion appear to be common conditions in these subjects. We also found that the use of newer generation sulfonylureas and insulin analogues increased during this period among our study subjects. A national survey is urgently needed to verify this epidemic and its implications.

ACKNOWLEDGMENT

The authors have nothing to disclose.

REFERENCES

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
3. Cryer PE. Banting lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994;43:1378-89.
4. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18:1415-27.
5. Duckworth W, Abraina C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
6. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Gethen S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
7. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glassiou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Man-
Ahn YB, Lee I. A nationwide survey about the current status of glycemic control and complications in diabetic patients in 2006: the committee of the Korean Diabetes Association on the epidemiology of diabetes mellitus. Korean Diabetes J 2009; 33:48-57.

20. Lee SA, Kim EY, Kim EH, Jeong JY, Jeong EH, Kim DW, Cho EH, Koh EH, Kim MS, Park JY, Lee KU. Anti-GAD antibody in patients with adult-onset diabetes in Korea. Korean Diabetes J 2009;33:16-23.